GlassScriptPhysician profile
Brooke Pate
NPI 1821531583
$9,583.09
in general payments reported to CMS, 2019-2025
33 companies · $2,140 in 2025
The $2,140 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $832 · 2022: $2,067 · 2023: $2,102 · 2024: $2,443 · 2025: $2,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,670 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,670.45 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,743.62 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,679.02 | 2021-2025 | |
| Novo Nordisk INC | $1,259.93 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $743.57 | 2022-2025 | |
| Lilly USA, LLC | $586.77 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $554.80 | 2021-2025 | Evenity, Prolia, Repatha |
| Dexcom, INC. | $519.06 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.13 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $264.37 | 2022 | |
| Abbott Laboratories | $234.33 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $220.97 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $168.61 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $149.79 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.73 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $130.45 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $127.67 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $124.58 | 2023-2024 | Cologuard Collection Kit |
| Vivus LLC | $78.61 | 2024 | Qsymia |
| Supernus Pharmaceuticals, INC. | $71.80 | 2022 | Tlando, Xyosted |
| Axsome Therapeutics, INC. | $55.47 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $47.95 | 2021-2022 | |
| Shield Therapeutics INC | $32.86 | 2023-2025 | Accrufer |
| Axonics, INC. | $32.72 | 2023 | Axonics |
| Currax Pharmaceuticals LLC | $31.46 | 2023-2024 | Contrave |
| Halozyme INC | $31.01 | 2023 | |
| Eisai INC. | $26.66 | 2021 | |
| Daiichi Sankyo INC. | $21.94 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $19.03 | 2022 | |
| Esperion Therapeutics, INC. | $18.51 | 2024 | Nexletol |
| Acella Pharmaceuticals, LLC | $18.50 | 2024 | NP Thyroid 60 |
| Amneal Pharmaceuticals LLC | $16.53 | 2025 | Unithroid |
| Mylan Specialty L.P. | $14.53 | 2021 | |
| Dynavax Technologies Corporation | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Pate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.